Anika Therapeutics (NASDAQ:ANIK) Earns “Sell (D-)” Rating from Weiss Ratings

Anika Therapeutics (NASDAQ:ANIK)‘s stock had its “sell (d-)” rating restated by equities research analysts at Weiss Ratings in a report issued on Thursday,Weiss Ratings reports.

Separately, Barrington Research reissued an “outperform” rating and issued a $15.00 price objective on shares of Anika Therapeutics in a research report on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Anika Therapeutics Stock Down 0.3%

Anika Therapeutics stock opened at $9.75 on Thursday. The company’s 50-day moving average price is $9.19 and its 200-day moving average price is $10.60. Anika Therapeutics has a twelve month low of $7.87 and a twelve month high of $24.12. The company has a market cap of $140.60 million, a PE ratio of -2.35 and a beta of 0.62.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Acadian Asset Management LLC increased its stake in Anika Therapeutics by 13.4% during the 1st quarter. Acadian Asset Management LLC now owns 539,614 shares of the biotechnology company’s stock valued at $8,107,000 after purchasing an additional 63,901 shares in the last quarter. HighTower Advisors LLC increased its stake in Anika Therapeutics by 57.1% during the 1st quarter. HighTower Advisors LLC now owns 20,971 shares of the biotechnology company’s stock valued at $315,000 after purchasing an additional 7,618 shares in the last quarter. Cerity Partners LLC acquired a new position in Anika Therapeutics during the 1st quarter valued at approximately $443,000. Envestnet Asset Management Inc. increased its stake in Anika Therapeutics by 38.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 95,634 shares of the biotechnology company’s stock valued at $1,437,000 after purchasing an additional 26,557 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Anika Therapeutics by 9.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 149,935 shares of the biotechnology company’s stock valued at $2,254,000 after purchasing an additional 12,473 shares in the last quarter. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.